AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27758944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 27758944 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin treatment in patients receiving tissue‐type plasminogen activator
Number of subjects: 104
Study 23494629 — intervention group
Group type: EXPERIMENTAL
Intervention: 200‐U onabotulinumtoxinA injections
Number of subjects: 72
Study 23494629 — intervention group
Group type: EXPERIMENTAL
Intervention: 300‐U onabotulinumtoxinA injections
Number of subjects: 72
Study 23494629 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 72
Study 23635051 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid coverage
Number of subjects: 12229
Study 23635051 — intervention group
Group type: COMPARATOR
Intervention: Control group (not selected for Medicaid)
Number of subjects: 12229
Study 19521435 — intervention group
Group type: EXPERIMENTAL
Intervention: Visante-OCT
Number of subjects: 101
Study 19521435 — intervention group
Group type: COMPARATOR
Intervention: SL-OCT
Number of subjects: 101
Study 19521435 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AS-OCT devices
Number of subjects: 101
Study 18416472 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior pelvic exenteration (PPE)
Number of subjects: 10
Study 18416472 — intervention group
Group type: COMPARATOR
Intervention: Standard resection
Number of subjects: 10
Study 16183426 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-LAM test
Number of subjects: 143
Study 16183426 — intervention group
Group type: EXPERIMENTAL
Intervention: TST and anti-LAM test
Number of subjects: 143
Study 12928982 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg daily) after a montelukast-free period of one day
Number of subjects: 16
Study 12928982 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg daily) after a montelukast-free period of three days
Number of subjects: 16
Study 10026401 — intervention group
Group type: EXPERIMENTAL
Intervention: Kerasal 5% ointment
Number of subjects: 9
Study 10026401 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylic acid 5% in petrolatum
Number of subjects: 9
Study 10026401 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylic acid 10% in petrolatum
Number of subjects: 9
Study 9017737 — intervention group
Group type: EXPERIMENTAL
Intervention: Odor present during recall after 5 days
Number of subjects: 40
Study 9017737 — intervention group
Group type: EXPERIMENTAL
Intervention: Odor present during recall after 15 min. and after 5 days
Number of subjects: 40
Study 9017737 — intervention group
Group type: COMPARATOR
Intervention: No odor present during any recall phase
Number of subjects: 40
Study 9017737 — intervention group
Group type: COMPARATOR
Intervention: No odor present during recall after 5 days
Number of subjects: 40
Study 2003053 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalosporins
Number of subjects: 30
Study 2003053 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillins
Number of subjects: 30
Study 2003053 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (Ilosone)
Number of subjects: 30
Study 2003053 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin ES
Number of subjects: 30
Study 6469092 — intervention group
Group type: EXPERIMENTAL
Intervention: Periaortic lymph node metastases
Number of subjects: 98
Study 6469092 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence
Number of subjects: 98
Study 6469092 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrences
Number of subjects: 98
Study 30768550 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (3‐min intervals at 40% and 80% V˙O2 reserve, n = 15)
Number of subjects: 45
Study 30768550 — intervention group
Group type: EXPERIMENTAL
Intervention: MICT (sustained 60% V˙O2 reserve, n = 15)
Number of subjects: 45
Study 30768550 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 45
Study 29190545 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise (aerobic and resistance)
Number of subjects: 47
Study 29190545 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 47
Study 29190545 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 47
Study 29190545 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise and resistance exercise
Number of subjects: 47
Study 27333960 — intervention group
Group type: EXPERIMENTAL
Intervention: Siberian ginseng powder
Number of subjects: 50
Study 27333960 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 24947287 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose edoxaban
Number of subjects: 21105
Study 24947287 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose edoxaban
Number of subjects: 21105
Study 24947287 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 21105
Study 22205098 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular hyaluronan injection
Number of subjects: 57
Study 22205098 — intervention group
Group type: COMPARATOR
Intervention: No intra-articular hyaluronan injection (non-injection group)
Number of subjects: 57
Study 22205098 — intervention group
Group type: COMPARATOR
Intervention: Comparison between injection and non-injection groups
Number of subjects: 57
Study 19757275 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg twice daily
Number of subjects: 66
Study 19757275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 17513645 — intervention group
Group type: EXPERIMENTAL
Intervention: Balsol (magnesium 1.5 g/L)
Number of subjects: 25
Study 17513645 — intervention group
Group type: EXPERIMENTAL
Intervention: Balsol plus additional magnesium (magnesium 3.0 g/L)
Number of subjects: 25
Study 17513645 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 25
Study 15181783 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal processing training program consisting of auditory and visual order threshold and sound localisation tasks over a period of eight weeks
Number of subjects: 42
Study 15181783 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 42
Study 11597539 — intervention group
Group type: EXPERIMENTAL
Intervention: Free and total PSA measurements in black participants (n = 868, 12%)
Number of subjects: 7183
Study 11597539 — intervention group
Group type: EXPERIMENTAL
Intervention: Free and total PSA measurements in Hispanic participants (n = 339, 4.7%)
Number of subjects: 7183
Study 11597539 — intervention group
Group type: EXPERIMENTAL
Intervention: Free and total PSA measurements across age groups
Number of subjects: 7183
Study 11597539 — intervention group
Group type: EXPERIMENTAL
Intervention: Free and total PSA measurements based on history of benign prostatic disease
Number of subjects: 7183
Study 11597539 — intervention group
Group type: EXPERIMENTAL
Intervention: %fPSA measurements across racial groups and age
Number of subjects: 7183
Study 9620898 — intervention group
Group type: COMPARATOR
Intervention: HR3 (rifampin plus isoniazid, 3 times weekly)
Number of subjects: 672
Study 9620898 — intervention group
Group type: EXPERIMENTAL
Intervention: HRp1 (rifapentine plus isoniazid, once weekly)
Number of subjects: 672
Study 9620898 — intervention group
Group type: EXPERIMENTAL
Intervention: HRp1.2/3 (rifapentine plus isoniazid, on 2 of 3 weeks)
Number of subjects: 672
Study 7890009 — intervention group
Group type: EXPERIMENTAL
Intervention: HELP-apheresis treatment
Number of subjects: 39
Study 2660333 — intervention group
Group type: EXPERIMENTAL
Intervention: ABO-matched random-donor platelet transfusions
Number of subjects: 60
Study 2660333 — intervention group
Group type: EXPERIMENTAL
Intervention: Second matched transfusion
Number of subjects: 60
Study 2660333 — intervention group
Group type: COMPARATOR
Intervention: Mismatched transfusions
Number of subjects: 60
Study 2660333 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched and mismatched platelet transfusions
Number of subjects: 60
Study 31138063 — intervention group
Group type: EXPERIMENTAL
Intervention: Half normal saline (0.45% saline in 5% dextrose)
Number of subjects: 168
Study 31138063 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (0.9% saline in 5% dextrose)
Number of subjects: 168
Study 30860114 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative DTI (Diffusion Tensor Imaging)
Number of subjects: 94
Study 30860114 — intervention group
Group type: COMPARATOR
Intervention: Non DTI (Control group)
Number of subjects: 94
Study 28338403 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐Moms (personalized health intervention via SmartPhone)
Number of subjects: 40
Study 28338403 — intervention group
Group type: COMPARATOR
Intervention: WIC Moms (usual care)
Number of subjects: 40
Study 25789568 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw-thrust manoeuvre in the 25° semi-sitting position
Number of subjects: 88
Study 25789568 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 88
Study 22992296 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination nicotine replacement therapy (NRT) for 6 weeks
Number of subjects: 987
Study 22992296 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination NRT for 2 weeks
Number of subjects: 987
Study 22992296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch alone for 6 weeks
Number of subjects: 987
Study 22992296 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 4-call counseling (SC) plus medication adherence counseling (MAC)
Number of subjects: 987
Study 22992296 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week combination NRT
Number of subjects: 987
Study 22992296 — intervention group
Group type: COMPARATOR
Intervention: 2-week nicotine patch only
Number of subjects: 987
Study 22992296 — intervention group
Group type: COMPARATOR
Intervention: 6-week nicotine patch only
Number of subjects: 987
Study 22992296 — intervention group
Group type: COMPARATOR
Intervention: 6-week combination NRT
Number of subjects: 987
Study 21600843 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (5 Hz, 900 stimuli) applied on 5 consecutive days
Number of subjects: 0
Study 21600843 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 0
Study 19686085 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 40 mg
Number of subjects: 0
Study 19686085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16403040 — intervention group
Group type: EXPERIMENTAL
Intervention: MoodGYM Mark II (new public version requiring compulsory completion of core assessments)
Number of subjects: 58200
Study 16403040 — intervention group
Group type: COMPARATOR
Intervention: MoodGYM Mark I (original site)
Number of subjects: 58200
Study 16403040 — intervention group
Group type: EXPERIMENTAL
Intervention: MoodGYM intervention (both versions)
Number of subjects: 58200
Study 15320650 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day creatine monohydrate supplementation (0.3 g.kg(‐1).d(‐1))
Number of subjects: 11
Study 15320650 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day creatine monohydrate supplementation
Number of subjects: 11
Study 15001036 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstained from eating during cue reactivity assessment
Number of subjects: 135
Study 15001036 — intervention group
Group type: COMPARATOR
Intervention: Ate during cue reactivity assessment
Number of subjects: 135
Study 9262289 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved embryos
Number of subjects: 0
Study 9262289 — intervention group
Group type: COMPARATOR
Intervention: Fresh embryos
Number of subjects: 0
Study 8250078 — intervention group
Group type: EXPERIMENTAL
Intervention: Nidek 3Dx system
Number of subjects: 100
Study 8250078 — intervention group
Group type: COMPARATOR
Intervention: Donaldson camera
Number of subjects: 100
Study 3569063 — intervention group
Group type: EXPERIMENTAL
Intervention: Ismo 20 (40 mg IS-5-N daily)
Number of subjects: 12
Study 3569063 — intervention group
Group type: EXPERIMENTAL
Intervention: Corangin 20 (40 mg IS-5-N daily)
Number of subjects: 12
Study 3569063 — intervention group
Group type: EXPERIMENTAL
Intervention: Corangin 40 (40 mg IS-5-N once a day)
Number of subjects: 12
Study 3569063 — intervention group
Group type: EXPERIMENTAL
Intervention: Corangin 60 (60 mg IS-5-N once a day)
Number of subjects: 12
Study 3569063 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release preparations (Corangin 40 and Corangin 60)
Number of subjects: 12
Study 30383673 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic acupuncture
Number of subjects: 104
Study 30383673 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo)
Number of subjects: 104
Study 27749578 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based intervention
Number of subjects: 150
Study 27749578 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-based intervention
Number of subjects: 150
Study 27749578 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (Control)
Number of subjects: 150
Study 24886681 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony‐stimulating factor (G‐CSF) for 5 days followed by autologous MSCs peripheral‐vein infusion
Number of subjects: 40
Study 24886681 — intervention group
Group type: COMPARATOR
Intervention: Regular liver‐supportive treatment only (control group)
Number of subjects: 40
Study 24886681 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC therapy
Number of subjects: 40
Study 22225697 — intervention group
Group type: EXPERIMENTAL
Intervention: GPM + DBT‐M treatment
Number of subjects: 60
Study 22225697 — intervention group
Group type: COMPARATOR
Intervention: GPM alone
Number of subjects: 60
Study 22225697 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness practice
Number of subjects: 60
Study 20041478 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-education aimed at improving knowledge, attitudes, and adherence behavior
Number of subjects: 0
Study 20041478 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial interventions targeting medication adherence as a secondary outcome
Number of subjects: 0
Study 20041478 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-education
Number of subjects: 0
Study 20041478 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centered approach considering risk factors for non-adherence
Number of subjects: 0
Study 17921245 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone technology for symptom monitoring
Number of subjects: 6
Study 16364056 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole orally for 2 days b.i.d.
Number of subjects: 10
Study 16364056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12530623 — intervention group
Group type: EXPERIMENTAL
Intervention: vdelta75 (75% of the difference between vLT and vVO2 max)
Number of subjects: 9
Study 12530623 — intervention group
Group type: EXPERIMENTAL
Intervention: vdelta50 (50% of the difference between vLT and vVO2 max)
Number of subjects: 9
Study 12530623 — intervention group
Group type: EXPERIMENTAL
Intervention: vdelta100 (100% of the difference between vLT and vVO2 max)
Number of subjects: 9
Study 10447055 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid cooling (L)
Number of subjects: 8
Study 10447055 — intervention group
Group type: EXPERIMENTAL
Intervention: Air cooling (A)
Number of subjects: 8
Study 10447055 — intervention group
Group type: COMPARATOR
Intervention: No cooling (N)
Number of subjects: 8
Study 8605781 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms ethinylestradiol and 75 micrograms gestodene
Number of subjects: 479
Study 8605781 — intervention group
Group type: COMPARATOR
Intervention: 20 micrograms ethinylestradiol and 150 micrograms desogestrel
Number of subjects: 479
Study 2179218 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion
Number of subjects: 0
Study 2179218 — intervention group
Group type: COMPARATOR
Intervention: Immobilization
Number of subjects: 0
Study 7384377 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental manipulation of signal value for 1 out of 10 stimuli presented 3 times in random order.
Number of subjects: 228
Study 7384377 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of the number of series presented to subjects (1, 2, and 3 series).
Number of subjects: 228
Study 7384377 — intervention group
Group type: COMPARATOR
Intervention: Variations such as increased motivation, auditory vs. visual stimuli, and different scoring procedures.
Number of subjects: 228
Study 31609896 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention
Number of subjects: 178
Study 31278767 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading (48 hours post-surgery)
Number of subjects: 24
Study 31278767 — intervention group
Group type: COMPARATOR
Intervention: Early loading (2 weeks after surgery)
Number of subjects: 24
Study 31278767 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Immediate and Early loading)
Number of subjects: 24
Study 28696373 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly upper limb rehabilitation for 24 weeks
Number of subjects: 31
Study 28696373 — intervention group
Group type: COMPARATOR
Intervention: No rehabilitation
Number of subjects: 31
Study 25857612 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-assisted dietary recording
Number of subjects: 110
Study 23686619 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based child sexual abuse prevention program
Number of subjects: 20
Study 23686619 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 20
Study 21724070 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% hydrogen peroxide bleaching agent during orthodontic treatment (group A)
Number of subjects: 40
Study 21724070 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% hydrogen peroxide bleaching agent after orthodontic treatment (group B)
Number of subjects: 40
Study 19183470 — intervention group
Group type: EXPERIMENTAL
Intervention: MM+CBT (dual doctor model)
Number of subjects: 140
Study 19183470 — intervention group
Group type: EXPERIMENTAL
Intervention: MM+I-CBT (single doctor model)
Number of subjects: 140
Study 19183470 — intervention group
Group type: COMPARATOR
Intervention: MM only (control group)
Number of subjects: 140
Study 17438504 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS 4IU)
Number of subjects: 40
Study 17438504 — intervention group
Group type: COMPARATOR
Intervention: Staples
Number of subjects: 40
Study 16739368 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole
Number of subjects: 180
Study 16739368 — intervention group
Group type: COMPARATOR
Intervention: 20 mg omeprazole MUPS
Number of subjects: 180
Study 16739368 — intervention group
Group type: COMPARATOR
Intervention: 40 mg esomeprazole
Number of subjects: 180
Study 16739368 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole
Number of subjects: 180
Study 16739368 — intervention group
Group type: COMPARATOR
Intervention: esomeprazole
Number of subjects: 180
Study 12873241 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-6 UK units of alcohol
Number of subjects: 80
Study 12873241 — intervention group
Group type: COMPARATOR
Intervention: 0 UK units of alcohol
Number of subjects: 80
Study 10561173 — intervention group
Group type: EXPERIMENTAL
Intervention: Para-aortic (PA) radiotherapy (30 Gy/15 fractions/3 weeks)
Number of subjects: 478
Study 10561173 — intervention group
Group type: COMPARATOR
Intervention: Dogleg (DL) radiotherapy (30 Gy/15 fractions/3 weeks)
Number of subjects: 478
Study 10561173 — intervention group
Group type: EXPERIMENTAL
Intervention: Para-aortic (PA) radiotherapy
Number of subjects: 478
Study 10561173 — intervention group
Group type: COMPARATOR
Intervention: Dogleg (DL) radiotherapy
Number of subjects: 478
Study 8687090 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by thymosin alpha1 + low-dose IFNalpha
Number of subjects: 22
Study 8687090 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (ifosfamide)
Number of subjects: 22
Study 1873513 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 74
Study 1873513 — intervention group
Group type: COMPARATOR
Intervention: Sodium Nitroprusside
Number of subjects: 74
Study 7087416 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-set Nonsense-Syllable Test presented monaurally at 90 dB SPL with cafeteria background noise at +20 dB S/N ratio
Number of subjects: 38
Study 7087416 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-set Nonsense-Syllable Test
Number of subjects: 38
Study 31253454 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma self-management responsibilities transferred from mother to child
Number of subjects: 15
Study 27613020 — intervention group
Group type: EXPERIMENTAL
Intervention: Banking Time
Number of subjects: 113
Study 27613020 — intervention group
Group type: COMPARATOR
Intervention: Business-as-Usual
Number of subjects: 113
Study 27613020 — intervention group
Group type: COMPARATOR
Intervention: Time-Control Comparison (Child Time)
Number of subjects: 113
Study 25715364 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFU combined with chemotherapy (group B)
Number of subjects: 185
Study 25715364 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (group A)
Number of subjects: 185
Study 24398076 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity intervention
Number of subjects: 232
Study 23025474 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental coding strategies (including temporal fine structure stimulation)
Number of subjects: 12
Study 23025474 — intervention group
Group type: COMPARATOR
Intervention: Personal TEMPO+ speech processors (control)
Number of subjects: 12
Study 19041284 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of sustained-release isradipine
Number of subjects: 24
Study 19041284 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 24
Study 17157900 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (500 mg bid)
Number of subjects: 97
Study 17157900 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 97
Study 15888797 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐alpha‐2b (1.5 mug/kg) once weekly plus daily ribavirin (1000‐1200 mg) for 24 weeks
Number of subjects: 287
Study 15888797 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐alpha‐2b (1.5 mug/kg) once weekly plus daily ribavirin (1000‐1200 mg) for 36 weeks
Number of subjects: 287